Gaithersburg, Maryland-based Novavax announced positive topline data from the company’s pivotal Phase III clinical trial of the seasonal flu vaccine NanoFlu.

Pfizer announced positive results from two Phase III trials, one in moderate-to-severe atopic dermatitis and another in pneumococcal disease.